+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1)



Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1)



Journal of Urology 172(1): 103-107



Due to the lack of specific markers the analysis of lymphatic vessel density (LVD) has been almost impossible in the past. We report the novel specific marker for lymphatic endothelium, lymphatic vessel endothelial hyaluronan receptor (LYVE-1), in prostatic, benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissue. Normal blood vessels were additionally quantified in BPH and PCa. LYVE-1 lymphatics (LVD) and CD34 blood vessels were assessed in 20 paraffin sections of BPH and 50 of PCa tissue by immunohistochemistry in a standardized experimental setting. The regions of PCa, periphery of the tumor and nontumorous regions of the PCa specimens, and BPH tissue were evaluated. Double staining was done (LYVE-1/CD34). Acquired data were interrelated and compared to the pathological parameters of the specimens. Double staining revealed numerous CD34 blood vessels but only a few LYVE-1 lymphatic vessels in BPH and PCa sections. Mean LVD +/- SD was distinctly lower (0.55 +/- 0.93) in PCa tissue than in tumor periphery (2.45 +/- 1.93) and nontumorous (3.16 +/- 2.23) tissue (p <0.0001). Maximum LVD was observed in BPH (7.17 +/- 3.61), which differed markedly from nontumorous areas of PCa specimens (p <0.001). In contrast to LVD, significantly more blood vessels were found in PCa (116.00 +/- 39.25) than in BPH (60.30 +/- 19.34) tissue (p <0.001). LYVE-1 is a specific lymphatic endothelial marker in benign and malignant prostate tissues. It is a useful new marker for the investigation of lymphatics. To our knowledge we report the immunohistochemical visualization and quantification of lymphatic vessels in prostatic tissue for the first time. In contrast to the stimulated angiogenesis of blood vessels in PCa, the destruction of lymphatic vessels occurs rather than lymphangiogenesis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049502573

Download citation: RISBibTeXText

PMID: 15201747

DOI: 10.1097/01.ju.0000128860.00639.9c


Related references

Homodimerization of the Lymph Vessel Endothelial Receptor LYVE-1 through a Redox-labile Disulfide Is Critical for Hyaluronan Binding in Lymphatic Endothelium. Journal of Biological Chemistry 291(48): 25004-25018, 2016

Lymph vessel destruction in prostatic cancer LYVE-1 as novel lymphatic marker. Pathology Research & Practice 199(4): 201, 2003

Binding of Hyaluronan to the Native Lymphatic Vessel Endothelial Receptor LYVE-1 Is Critically Dependent on Receptor Clustering and Hyaluronan Organization. Journal of Biological Chemistry 291(15): 8014-8030, 2016

Ectodomain Shedding of Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE-1) Is Induced by Vascular Endothelial Growth Factor A (VEGF-A). Journal of Biological Chemistry 291(20): 10490-10500, 2016

Evidence for lymphatic destruction in prostate carcinoma assessed with the novel lymphatic marker LYVE-1. European Urology Suppl.s 2(1): 162, 2003

Tumor-induced lymphangiogenesis and lymphatic vessel (LV) invasion of pancreatic carcinoma in the peripheral nerve plexus. High-density area of LVs in peripancreatic tissue. Lymphatic endothelial cells stained by D2-40 (brown-yellow) and pancreatic cancer. Cancer Science 103(10): October Cover-October Cover, 2012

Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression. RadioTherapy and Oncology 77(2): 172-175, 2005

Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. Journal of Pathology 209(1): 67-77, 2006

Lymphatic vessel endothelial hyaluronan receptor-1 is a novel prognostic indicator for human hepatocellular carcinoma. Molecular and Clinical Oncology 1(6): 1039-1048, 2013

Lymphatic vascular endothelial hyaluronan receptor (LYVE)-1- and CCL21-positive lymphatic compartments in the diabetic thymus. Anatomical Science International 81(4): 201-209, 2006

Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle. Journal of Histochemistry and Cytochemistry 59(2): 167-179, 2011

Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Investigative Ophthalmology & Visual Science 46(12): 4536-4540, 2005

The expression of the lymphatic endothelial cell marker LYVE-1 in benign and malignant vascular tumours. Journal of Pathology 201(Suppl.): 57A, 2003

Lymphatic vessel invasion detected by the endothelial lymphatic marker D2-40 (podoplanin) is predictive of regional lymph node status and an independent prognostic factor in patients with resected esophageal cancer. Folia Histochemica et Cytobiologica 49(1): 90-97, 2011

Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelium cell markers D2-4 and LYVE-1 Correlation with pathologic parameters and clinical outcome. Urologic Oncology: Seminars and Original Investigations 31(7): 1386-1394, 2013